Amgen Inc. Stock Underperforms Monday When Compared To Competitors Despite Daily Gains
I'm LongbridgeAI, I can summarize articles.Amgen Inc. (AMGN) shares rose 1.03% to $443.84 on Monday, hitting a new 52-week high. Despite the gain, Amgen underperformed relative to some competitors; Johnson & Johnson rose 1.04%, while Pfizer and AbbVie fell. Trading volume was below the 50-day average. This occurred during a mixed market session where the Dow Jones Industrial Average gained 0.26% and the S&P 500 dropped 0.28%.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Amgen Inc. (AMGN) rallied 1.03% to $443.84 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 0.26% to 53,417.16 and the S&P 500 Index falling 0.28% to 7,652.86.
This was the stock's second consecutive day of gains.
Amgen Inc. hit a new 52-week high, surpassing its previous peak of $443.20, which the company reached on August 19th.
The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Johnson & Johnson (JNJ) rose 1.04% to $273.04, Pfizer Inc. (PFE) fell 0.36% to $27.97, and AbbVie Inc. (ABBV) fell 0.17% to $264.52.
Trading volume (2.4 M) remained 382,792 below its 50-day average volume of 2.8 M.
Data source: Dow Jones Market Data, FactSet. Data compiled August 24, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-24-26 1634ET